Adial Pharmaceuticals is now Azora Therapeutics (NASDAQ: AZR). Read more →
Azora Therapeutics | Accessibility Statement

Accessibility Statement

Effective September 1, 2026

Our commitment

Azora Therapeutics is committed to making this website usable by everyone, including people who browse with a screen reader, navigate by keyboard, rely on captions, or need to enlarge text or reduce motion. Accessibility is treated as part of building the site, not as a later correction.

The standard we work to

We aim to conform to the Web Content Accessibility Guidelines (WCAG) 2.1, Level AA, published by the World Wide Web Consortium. These guidelines are the reference point used by many regulators and form the basis of our accessibility reviews.

What we have done

  • Structure. Pages use semantic HTML landmarks and a logical heading order, so assistive technology can describe and skip between regions.
  • Keyboard. Primary navigation, links, buttons, forms and dialogs are designed to be reached and operated by keyboard. A skip link jumps past the navigation to the main content, and dialogs support keyboard dismissal and focus management.
  • Visible focus. A high-contrast focus outline is shown on focusable elements and is not intentionally suppressed.
  • Colour and contrast. Body text and headings are set in colours chosen to meet AA contrast against their backgrounds. Colour is not intended to be the only means of conveying information.
  • Images and figures. Meaningful images carry alternative text. Decorative images are marked so screen readers pass over them rather than announcing them.
  • Motion. If your system is set to reduce motion, site animations and scroll effects are reduced or disabled and background video playback is suppressed.
  • Interactive science content. The three-dimensional receptor viewer is supplementary. The page provides a text description and a link to the underlying structure in a full external viewer, so essential information does not depend on operating the model.
  • Responsive text. Layouts are designed to reflow and remain readable when text is enlarged or the window is narrow, without loss of content or horizontal scrolling.

Known limitations

We want to be straightforward about areas that may not yet provide an equivalent experience:

  • The interactive protein viewer is supplied by a third-party library and is not fully operable by keyboard. The accompanying description and external structure link are provided for this reason.
  • Some content is delivered by third-party platforms, including our investor relations provider. We ask our vendors about accessibility but we do not control their code.
  • Documents published as PDFs, such as SEC filings sourced from EDGAR, may not be fully tagged for accessibility. We will supply an accessible alternative on request when practical.

How we test

Our review process includes automated checking, keyboard-only navigation, responsive-layout checks and assistive-technology evaluation where available. We retest when significant changes are made and record confirmed limitations on this page.

Tell us about a barrier

If any part of this site is difficult or impossible for you to use, please tell us. Include the page address, what you were trying to do, and the browser and assistive technology you were using, if you know them. We will work to resolve the problem and provide the information you were seeking in another format when possible.

Azora Therapeutics, Inc.
Attn: Accessibility
4870 Sadler Road, Suite 300
Glen Allen, VA 23060
Email: info@azoratherapeutics.com
1-804-487-8196

Formal complaints

If you are not satisfied with our response, you may escalate the matter to us in writing at the address above. This statement does not limit any right you have under applicable accessibility or disability law.

Azora Therapeutics
Investigational Products

AT177 and Azora Therapeutics’ other product candidates are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established, and no conclusion regarding safety or efficacy can or should be drawn from the information presented on this website. Clinical and preclinical findings described here, including findings relating to indigo naturalis, are drawn from published third-party research and from company data on file; results observed with any other agent are not predictive of results that may be observed with AT177. Nothing on this site is medical advice, an offer to sell or a solicitation to buy any security, or a promotion of any unapproved product or unapproved use of a product.

Trademarks

Azora™, Azora Therapeutics and the Azora logo are trademarks of Azora Therapeutics, Inc. All other product names, logos, brands and trademarks appearing on this site are the property of their respective owners. Their use does not imply any affiliation with, endorsement or sponsorship by, or partnership with those owners, and Azora Therapeutics asserts no ownership of or right in those marks. Where third-party products are referenced, they are referenced solely to describe the prior professional experience of members of Azora’s team and advisors.

Forward-Looking Statements

This website contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development of AT177, planned IND filing and clinical trials, anticipated timing of data, market opportunity, and intellectual property. These statements are based on current expectations and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially. Product candidates are investigational, have not been approved by the FDA or any regulatory authority, and their safety and efficacy have not been established. Market, competitive, and clinical figures presented are drawn from company materials and third-party sources and are subject to review. Azora undertakes no obligation to update any forward-looking statement except as required by law. Please refer to the company's filings with the U.S. Securities and Exchange Commission for additional information.

NASDAQ: AZR  ·  © 2026 Azora Therapeutics, Inc. All rights reserved.  ·  Privacy Policy  ·  Terms of Use  ·  Accessibility Statement